COSA 2021: Safety and Tolerability of Sitravatinib + Tislelizumab and Antitumor Activity are Shown in Advanced PROC
The combination is undergoing phase 1 study.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.